Biotransplant and method for treating the cases of osteoporosis
FIELD: medicine; medical engineering.
SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material. The tissue is subjected to disaggregation and the produced cell suspension is resuspended and cultivated on growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulate mature stroma in cell culture. Method involves intravenously dropping mesenchyma stem cell culture in the amount of 50 to 500 mln in 50-100 ml of physiologic saline.
EFFECT: accelerated recovery of bone tissue; positive biochemical factors dynamics; improved patient locomotor activity.
The invention relates to the culture of genetically non-modified mesenchymal stem cells and treatment of osteoporosis.
The urgency of the problem of osteoporosis is confirmed by the results of large-scale long-term epidemiological studies showing the prevalence of osteoporosis in the population, a significant negative impact of this disease on health status and significant economic damage.
Osteoporosis is a systemic skeletal disease characterized by low bone density and impaired trabecular microarchitecture bone. Increasing the fragility of the bones increases the risk of fractures, which represents one of the most important clinical aspects of the disease.
Treatment of osteoporosis is a difficult task, because the disease has a heterogeneous nature and usually diagnosed late, when there are already fractures and irreversible changes in the bones. It is long, with spontaneous exacerbations and periods of remission, requires a lot of patience and active participation of the patient in the treatment process, since the effect can manifest after a long period of time. The goal of treatment is slowing or temporarily stopping the loss of bone mass, is a voiding of bone fractures the improved condition of the patient, increasing his physical activity, the maximum vocational rehabilitation, improvement of quality of life.
Treatment of osteoporosis is based on three principles: etiological, pathogenetic, symptomatic. Etiological principle is the treatment of the underlying disease with secondary osteoporosis. This requires correction or cancel "iatrogenic" against osteopenia drugs. However, because of the disease, a symptom of which is osteoporosis, often have a chronic course, "iatrogenic" drugs are in many cases essential. Therefore, the etiological principle is not always radical. Pathogenesis - the basic principle in the treatment of primary and many variants of secondary osteoporosis. It is aimed at suppression of increased bone resorption, on the stimulation of bone formation or normalization of both processes of bone remodeling. Symptomatic principle involves applying balanced for calcium, phosphorus and protein diets, prescriptions calcium salts, using dosed exercise and physical therapy, physical therapy techniques, orthopedic treatment, painkillers [Nasonov EL, 2000].
Currently, the main groups of drugs for pathogene the ical treatment of osteoporosis include drugs, inhibiting bone resorption (estrogens, selective estrogen receptor modulators, calcitonin, biphosphonates, calcium; drugs that stimulate bone formation (fluoride, parathyroid hormone, growth hormone, anabolic steroids, androgens, drugs multifaceted actions (active metabolites of vitamin D, ossein-hydroxyapatite complex, ipriflavon, compounds containing phosphates, strontium, silicon, aluminum, thiazides) [Rozhen L.Y., 2000].
Regeneration of the bone tissue damage and systemic resorption occurs at the expense of mesenchymal stem cells (MSCS), which are precursors of osteoblasts and contribute to the formation of resurfacing units. Currently, the use of MSCS for systemic and local bone regeneration finds increasing application [Jorgensen, S., et al, 2001].
Published results from clinical trial of transplantation of mesenchymal stem cells from bone marrow of children with impaired osteogenesis. Six children with a genetic defect in skeletal development (osteogenesis imperfecta) was performed at two infusion labeled allogeneic mesenchymal bone marrow cells. In 5 patients cells engrafted in one or more organs (bones, skin, bone marrow stroma). After treatment there was an increase in the rate of growth of patients during the first months after transplantation. Relatively short effect and rapid loss of cell researchers explain the immune reaction of the recipient, which is one of the major drawbacks of using adult neautrogena cells of donor mesenchymal cells [R. Smith, 2001].
Most researchers prefer autologous cells (bone marrow cells, peripheral blood). Advantages autotransplants are obvious, but there are a number of restrictions on their use. In particular, the duration of the growing cell cultures - more than 2 months may be critical for some patients; cells derived from elderly and seriously ill people have a low capacity for proliferation and self-renewal.
In comparison with autologous cell transplant donor material (including fetal) cells possess a number of advantages:
fetal cells have a greater potential for growth and proliferation, a pronounced ability to differentiation and functionally more active, produce growth factors and regeneration;
transplanted fetal cells stimulate angiogenesis;
fetal cells and tissues more resistant to hypoxia and cold preservation;
culture of donor cells can be prepared in advance and used on demand.
The most pronounced of therapeuti the definition potential at pathologies of bone tissue possess mesenchymal stem cells, able to fill the required number of osteoblasts and, accordingly, resurfacing units of bone tissue. Being unique "factory" cytokines and growth factors, donor MSC serve as a catalyst for their own body reserves. Mesenchymal stem cells are usually obtained from donor bone marrow, but there are other sources of skeletal muscle, subcutaneous adipose tissue, fetal organs disorders (liver, thymus, spleen). MSCS from fetal organs disorders and methods of obtaining them has not been studied. Describes the methods of cultivation of MSC from bone marrow and lipoaspirates allow to obtain a heterogeneous population of stromal cells, only a small percentage of which are stem. Cells Mature stroma does not have the ability to differentiate into various cell lines and, therefore, therapeutically ineffective. After transplantation of stromal cells migrate mainly in connective tissue and accumulate there. In the standard passirovannye in high crop doses, the proportion of Mature stromal cells increases rapidly.
Use as graft homogeneous (at least 80%of the population of pluripotent MSC allows to increase the effectiveness of treatment, to increase the reproducibility of results and to avoid unwanted effect is.
The objectives of the present invention are getting biotransplant for complex pathogenetic therapy of osteoporosis, which is evidenced by a significant increase in mineral bone density (BMD) or the termination of its loss according to densitometry, the dynamics of the main biochemical indicators to assess bone formation (alkaline phosphatase, osteocalcin) or reduction of bone resorption (urinary excretion of calcium, deoxypyridinoline), the lack of new bone fractures, improve the General condition of the patient, reducing pain in the bones, increasing motor mode, to improve the quality of life of the patient.
To achieve the objectives of the proposed group of inventions, United by a common inventive concept.
Biotransplant for the treatment of osteoporosis contains mesenchymal stem cells (MSC)derived from fetal donor or autologous material, and the cloth desagregirutee, the cell suspension resuspended and cultured in growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulation in cell cultures of Mature stroma.
As fetal material used tissues: bone marrow, thymus, liver, adipose tissue of human embryos in the 1st trimester pregnant the spine.
As a donor material used tissues: bone marrow, thymus, liver, adipose tissue.
As autologous material used tissues: bone marrow, adipose tissue.
Biotransplant intended for intravenous administration. Also we propose a method for the treatment of osteoporosis, namely, that the patient intravenous infusions of biotransplant according to claim 1, comprising from 50 to 500 million mesenchymal stem cells.
MSC with primary capacity for osteogenic differentiation extracted from fetal (bone marrow, thymus, liver, adipose tissue) or donor (bone marrow, adipose tissue, thymus tissue or autologous material (bone marrow, adipose tissue). For isolation of fetal cells using abortifacient material obtained in the artificial termination of pregnancy in healthy women, pre-screened for the presence of viral and bacterial infections.
The use of biomaterial is achieved on the following periods of gestation: liver - 5-8 weeks, thymus - 18-20 weeks, bone marrow - 17-20 weeks, subcutaneous adipose tissue - 17-19 weeks. If the selection of cells produced from aspirates (bone marrow, lipoaspirate), and from the dense tissues such as the thymus, the organ pre-ground and enzymatic desagregirutee. The suspension is filtered through melmacian the first stainless steel sieve. Cell suspension (aspirate) was diluted 1:1 with saline Hanks, centrifuged at 1,500 mode×g, 10 minutes and resuspended in the growth medium DMEM/F12 containing 15% fetal calf serum, selected for silage preparation for cell cultivation in a low-density, 2 mm glutamine. The suspension of cells plated on plastic Petri dishes with a diameter of 100 mm seeding primary cell suspension is 1-20 million mononuclear cells on 1 cm2depending on the source selection. After 1 day neprecejusies cells are removed, the growth medium replaced. The culture is incubated at 37°C in an atmosphere of 5% CO2. After 6 days see the growth of heterogeneous cell populations. Upon reaching the culture 50% confluently monolayer trypsinized and subcultured on new Cup with a density of 10-30 cells per 1 cm2in the growth medium, additionally containing 10 ágml transferrin, 1 μg / ml insulin, 10 ngml fibroblast growth factor - 2 and 8 IUml heparin. 7-10 days away dense colonies of small cells (7-10 µm in diameter) with a large number of mitoses. Selected colonies scatter in new Cup with a density of 20 cells / cm2and grow to preconferences. Replacement environment produce every 2 days. Subsequent passages produced in the same mode. Increasing sowing dose or change the level of growth environment leads to rapid accumulation in cell cultures of Mature stroma. Experimentally selected conditions, unifying criteria for the selection of the source material and the mode of cultivation, are optimal for achieving the following results.
The selection of sources for MSC allows to obtain a cell culture with primary capacity for osteogenic differentiation.
The mode of cultivation and selective culture media allow for multiple passirovannye to maximize homogeneous cell culture undifferentiated cells.
The mode of cultivation and selective culture media allow you to maintain pluripotency of cell cultures.
The mode of cultivation and selective culture media allow you to get a large number of cells for transplantation (series)that ensures the reproducibility of the results.
The method of treatment is based on the experimentally proven fact reparative action of mesenchymal stem cells.
Transplantation is carried out in therapeutic conditions or any relevant Department in the presence of a General practitioner. Before transplantation, providing biological sample. The solution of mesenchymal stem cells attached to the patient, inkjet shimmers 0.5 ml, after which the system block. The recipient investigate complaints status is e, pain, measured blood pressure and count the pulse. Signs of biological incompatibility are a pain in the lumbar, epigastric regions, headaches, chest pain, feelings of fear, the presence of perspiration and swelling of the face, lower blood pressure, increased heart rate. The test is repeated three times. If negative, proceed to transplantation.
Culture of mesenchymal stem cells is diluted in 50 ml of physiological solution, thoroughly mixed, injected intravenously at a rate of 10 ml/min
Within 24 hours after the transplantation the patient is to be observed in therapeutic Department.
The effectiveness of the proposed method is to increase bone density according to densitometry, the dynamics of biochemical parameters and improve motor activity of the patient.
Surveyed 11 women, whose average age was 56,9±to 2.57 years. Prescription menopause - from 1 year to 6 years. All patients underwent clinical, laboratory and instrumental studies, including determination of growth, body weight, level of calcium in the serum and the daily excretion of urine, acid and alkaline phosphatase, the daily excretion of hydroxyproline in the urine. Performed x-rays of the thoracic and lumbar regions of pozvonok the ICA in two projections and ultrasound densitometry. All patients spent transplantation of mesenchymal stem cells on the proposed method.
In the analysis of subjective data of the study revealed that in both groups the most common were complaints about back pain, pain in the extremities. General weakness noted 5 of 11 patients.
In a laboratory study patients showed increased levels of acid phosphatase to 0.25+0.014 mmol/h/l and a daily excretion of hydroxyproline in urine to 43,8±2,50 mg/day, indicating activation of bone resorption in these patients. The radiological examination of the spine in patients identified osteoporosis. In 6 patients detected fractures of one of the thoracic or lumbar vertebra. When densitometric study in all patients there was a decrease SHOWS more than 2.5 standard deviations, indicating that they have osteoporosis.
According to the 6 months and 1 year of clinical, laboratory and instrumental study noted positive dynamics of subjective and objective indicators. Thus, after treatment significantly decreased the number of patients presenting with complaints on pain in the back and lower limbs.
For biochemical analysis revealed significant decrease in the content of acid phosphatase (from 0.25±0,014 to 0.20±0.015 mmol/h-l; p<0,1) and daily excretion of urine hydroxyproline (from 43.8± 2.5 to 29,7±2.4 mg/day; p<0.05)and a decrease in the content of osteocalcin (from 22.5±a 4.3 to 10.4±4,2 ng/ml; p<0.05)and alkaline phosphatase (1,44±0.09 to 1,19±0.08 mmol/h-l; p<0,05), the daily excretion of calcium in the urine (380±18.7 to 290±17.9 mg/days; p<0.01) and hydroxyproline (52,1±2,6 to 31.2±2.4 mg/day; p<0,05).
The radiological examination of new fractures of the thoracic and lumbar spine during treatment is not revealed. When densitometric study patients showed increased SHOW 1.1%
1. Biotransplant for the treatment of osteoporosis, characterized in that it contains mesenchymal stem cells (MSC)derived from fetal donor or autologous material, and the cloth desagregirutee, the cell suspension resuspended and cultured in growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulation in cell cultures of Mature stroma.
2. Biotransplant according to claim 1, as fetal material used tissues: bone marrow, thymus, liver, adipose tissue of human embryos in the 1st trimester of pregnancy.
3. Biotransplant according to claim 1, as a donor material used tissues: bone marrow, thymus, liver, adipose tissue.
4. Biotransplant according to claim 1, as an autologous material used tissues: bone marrow, adipose tissue.
5. Biotransplant according to claim 1 intended for intravenous administration.
6. A method of treating osteoporosis, characterized by the fact that the patient intravenous infusions of biotransplant according to claim 1, comprising from 50 to 500 million mesenchymal stem cells.
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel substituted 2-aryl-3-(heteroaryl)imidazo[1,2-a]-pyrimidines of the formula (I):
or to their pharmaceutically acceptable salts wherein: (a) R1 is taken among the group consisting of -NH2, C1-5-alkylamino-, di-C1-5-alkylamino-, phenylmethylamino-group; (b) Y is taken among the group consisting of hydrogen atom (H), halogen atom, piperidine, OR4, SR4, -SO2CH3, NHR4 and NR4R5 wherein R4 and R5 are taken independently among hydrogen atom (H), α-alkylphenyl-C1-5-alkyl, linear or branched alkyl substituted optionally with C3-5-carbocycle, phenyl or substituted phenyl wherein indicated phenyl can be substituted with one or some substituted taken among C1-5-alkoxy-group; (c) R2 represents from one to five members taken independently among the group including hydrogen atom (H), halogen atom, trifluoromethyl; (d) R3 represents hydrogen atom (H), or radicals R3 taken in common form aromatic ring; (e) X represents nitrogen atom (N) or -CH. Also, invention relates to methods for preparing indicated compounds and to a method for treatment based on these compounds. Invention provides preparing novel compounds that can be used in relief states by reducing the level of inflammatory cytokines, for example, the indicated state represents proliferative (rheumatic) arthritis.
EFFECT: valuable medicinal properties of compounds and compositions.
40 cl, 1 tbl, 4 ex
FIELD: medicine, phytotherapy, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to using Belamcanda chinensis extract for preparing organ-selective medicinal preparation without uterotropic effect or with minimal such effect that is used as estrogen-like preparation. This preparation is used in selective treatment and/or prophylaxis of cardiovascular diseases, in particular, atherosclerosis and osteoporosis, climacteric disturbances, especially for prophylaxis or softening congestions of blood. Extract is used in manufacturing a medicinal preparation in ready formulation for selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerosis, and for selective treatment and/or prophylaxis of osteoporosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood. Extract promotes to effective prophylaxis and/or treatment of cardiovascular diseases, in particular, atherosclerosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood.
EFFECT: valuable medicinal properties of extract.
4 cl, 4 ex
FIELD: organic chemistry, vitamins, medicine, pharmacy.
SUBSTANCE: invention relates to a new compound of the formula (I): wherein X means hydrogen atom or hydroxy group; R1 and R2 that can be similar or different mean hydrogen atom, (C1-C4)-alkyl; R3 means hydrogen atom, methyl group, fluorine or chlorine atom. Also, invention relates to its esters able to hydrolysis in vivo in combination with pharmaceutically acceptable acids. Also, invention relates to a pharmaceutical composition eliciting the inhibitory activity with respect to proliferation and promoting differentiation of cells and comprising the effective dose of compound of the formula (I) in common with pharmaceutically acceptable carriers and/or excipients. Also, invention relates to applying compound of the formula (I) for preparing a medicine used in treatment and prophylaxis of disease characterizing by abnormal differentiation of cells and/or proliferation of cells.
EFFECT: valuable medicinal properties of compounds.
13 cl, 3 sch, 3 tbl, 6 ex
FIELD: medicine, chemical-pharmaceutical industry.
SUBSTANCE: invention relates to new applying EP4 receptors agonist for treatment and/or prophylaxis of diseases associated with loss of osseous mass. Agonists of EP4 receptors show high effectiveness in treatment of diseases associated with loss of osseous mass, among the, as osteoporosis of different genesis. Agonists of EP4 receptors involve prostaglandin skeleton base.
EFFECT: valuable medicinal properties of pharmaceutical composition.
16 cl, 3 tbl, 5 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new derivatives of indol-3-yl of the formula (I):
wherein each A and B represents independently of one another oxygen atom (O), NH, CONH, NHCO or a direct bond; X means (C1-C2)-alkylene or a direct bond; R1 means hydrogen atom (H); R2 means hydrogen atom (H); R3 means NHR6, -NR6-C(=NR6)-NHR6, -C(=NR6)-NHR6, -NR6-C(=NR9)-NHR6, -C(=NR9)-NHR6 or Het1; each R4 and R5 represents independently of one another hydrogen atom (H); R7 means -(CH2)o-Ar, Het, OR6; R6 means hydrogen atom (H); R7 means (C1-C10)-alkyl, (C3-C10)-cycloalkyl; R8 means Hal, NO2 (nitro-group), CN (cyano-group), Z, -(CH2)o-Ar, COOR1, OR1, CF3, OCF3, NHR1; R9 means CN or NO2; Z means (C1-C6)-alkyl; Ar means aryl that can represent unsubstituted, monosubstituted, or polysubstituted R8; Hal means F, Cl, Br, J; Het means saturated, partially or completely saturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members wherein 1 or 2 nitrogen atom (N) and/or 1 or two sulfur atom (S) present, and heterocyclic radical can be monosubstituted with phenyl; Het1 means saturated, partially or completely unsaturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members and from 1 to 4 nitrogen atoms (N) that can be unsubstituted or monosubstituted NHX, or oxo-group; n = 0, 1 or 2; m = 0, 1, 2, 3, 4, 5 or 6; o means 0, 1 or 2; and their physiologically acceptable salts and solvates. Compounds of the formula (I) elicit intergin-inhibitory effect that allows their using as components of pharmaceutical composition. Also, invention describes intermediate compounds.
EFFECT: valuable medicinal properties of compounds.
11 cl, 4 sch, 1 tbl, 34 ex
SUBSTANCE: on should apply the suggested compound of formula 1 for treating and/or preventing osteoporosis and related osseous diseases.
EFFECT: higher efficiency of therapy and prophylaxis.
7 cl, 2 dwg, 21 ex, 6 tbl
FIELD: organic synthesis.
SUBSTANCE: invention provides compounds of general formula I:
in which R1 represents H, halogen, OCH3, or OH; R2 represents (a) -X-(CH2)n-CH2-N(R4)R5, where (i) X represents NH or S; n is integer from 1 to 4; R4 and R5, the same or different, represent C1-C4-alkyl, H, -CH2C≡CH, or -CH2CH2OH; or R4 and R5, together, form nitrogen-containing five- or six-membered cycle or heteroaromatic cycle; or where (ii) X represents O; n is integer from 1 to 4; one of R4 and R5 is CH2C≡CH, or -CH2CH2OH and the other H or C1-C4-alkyl; or R4 and R5, together, form imidazole cycle or nitrogen-containing six-membered cycle or heteroaromatic cycle; or R2 represents (b) -Y-(CH2)nCH2-O-R5, where (i) Y represents O; n is integer from 1 to 4; and R6 represents -CH2CH2OH or -CH2CH2Cl; or where (ii) Y represents NH or S; n is integer from 1 to 4; and R6 represents H, -CH2CH2OH, or -CH2CH2Cl; or R2 represents (c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, or 2,2-diethyl-2-hydroxy-ethoxy; R3 represents H. halogen, OH, or -OCH3. Claimed compounds are novel selective estrogen receptor modulators. Invention also discloses pharmaceutical composition and a method for production of tissue-specific estrogenic and/or antiestrogenic effect in patient, for whom indicated effect is required.
EFFECT: increased choice of estrogen receptor modulators.
19 cl, 7 tbl, 11 ex
SUBSTANCE: method involves administering selective modulator of steroid sex hormones being in particular compounds of general formula(I) and some quantity of steroid sex hormones precursor selected from a group composed from dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-en-3β,17β-diol and compounds in vivo transformable into one of cited precursors. Bisphosphonates combined with selective estrogen receptor modulators and/or steroid sex hormones precursor are additionally introduced for medically treating and/or inhibiting osteoporosis progress.
EFFECT: enhanced effectiveness of treatment; excluded adverse side effects.
41 cl, 13 dwg, 4 tbl
FIELD: medicine, therapy.
SUBSTANCE: simultaneously for 20 d one should prescribe calcium D3 two times daily in the morning and in the evening per 1 tablet or Beresh Plus drops. The quantity of drops for daily intake is equal to patients body weight in kg and they should be introduced in three stages during meals by drinking them up with sufficient amount of water. Application of the suggested method optimizes calcium exchange in patients with osteoporosis, enables to achieve earlier and more stable results in normalization of calcium content in bones by preventing, thus, osteoporotic fractures.
EFFECT: higher efficiency of pharmacological correction.
FIELD: organic synthesis.
SUBSTANCE: invention provides compounds of general formula I:
, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.
EFFECT: increased choice of cysteine protease inhibitors.
34 cl, 1 tbl, 13 ex
FIELD: medicine, gerontology.
SUBSTANCE: beforehand one should detect human biological age and the age of human immune system to compare them with human calendar age: in case of predominance of at least one of them against calendar age one should once introduce the suspension of human fetal tissues into subcutaneous fiber of anterior abdominal wall. For this purpose one should apply fetal tissues being heterogeneous by their histogenesis and, also, preparations of placental origin. The innovation provides normalization of immunocytogram values and, thus, similarity of calendar and biological age for 1 yr.
EFFECT: higher efficiency of correction.
SUBSTANCE: biotransplant has active ingredient like culture of genetically unmodified neuron trunk cells taken from anterior brain of the first pregnancy trimester human embryo or periventricular region of brain of 15-20 gestation weeks and selectively reproduced under cultivation conditions to the amount of 107-109 pluripotent non-differentiated cells in neurospheres having 50-500 mln of neuron trunk cells and 2 ml of physiologic saline. Method involves introducing 50-500 mln of neuron trunk cells and 2 ml of physiologic saline in one stage in endolumbal way.
EFFECT: enhanced effectiveness of treatment; accelerated repair and improvement of injured brain functions; stable treatment results.
5 cl, 1 tbl
FIELD: biopharmacology, medicine.
SUBSTANCE: the suggested biotransplant contains an active component: the culture of genetically unmodified neuronal stem cells (NSC) obtained out of anterior cerebral tissue of human embryos of the 1st trimester of pregnancy or periventricular cerebral area of 15-20 wk gestation and selectively multiplied under cultivating conditions up to the quantity of 10 (7) - 10 (9) pluripotent undifferentiated cells in composition of neurospheres, at the content of NSC being 50-500 mln., and 2 ml physiological solution. The method for treating ischemic insult deals with introduction of 50-500 mln. NSC in 2 ml physiological solution. The suggested biotransplant and method for treating ischemic insult enable to quickly restore and improve cerebral functions.
EFFECT: shortened terms of therapy.
5 cl, 2 ex, 1 tbl
FIELD: veterinary medicine.
SUBSTANCE: the present innovation deals with methods to activate the activity of protective mechanisms and organs of hormonal regulations. One should introduce a tissue preparation for an animal, moreover, to obtain it is necessary to apply 2.5 g pregnant or postpartum uterus, per 1.5 g thyroid, parathyroid and thymus glands, 2.0 g pancreas, 2.5 g liver all purified against spare tissues from clinically and hematologically healthy animals from cattle group up to 4-6-yr-aged period. The organs mentioned should be reduced, then tissue mixture obtained should be mixed with fresh running water at 1:2 ratio to obtain emulsion to be thermally treated in water bath at 58-59 C. After cooling emulsion should be supplemented with formalin, ACD f-2 and natural bee honey to obtain the following ratio of components in ready-to-use product: tissue emulsion 10 g, 68.7%; ACD f-2 1.5 g, 10.3%; formalin 0.006 g, 0.4%; natural bee honey 3.0 g, 20.6%. Before being introduced for an animal one should carefully mix preparation to detect its dosage at 0.02-0.5 ml/kg animal body weight to be then introduced per Ѕ parts from the right and from the left into dorsal lumbar muscles either once or twice at interval of 7-9 d. The method enables to perform complex biostimulating and hormonal impact upon animal body due to keeping active substances of tissue preparation being obtained due to above-mentioned technique.
EFFECT: higher efficiency of prophylaxis and therapy.
FIELD: veterinary science.
SUBSTANCE: one should apply a honey-tissue preparation that contain emulsion out of the walls of pregnant uterus and ovaries without cow's yellow bodies 6.0 ml, natural bee honey 5.0 g, isotonic sodium chloride solution 2.0 ml sodium benzoate caffeine 1.5 g to be introduced into dorsal lumbar muscles both from the right and from the left per a half of the dosage being equal to 0.03-0.04 ml/kg either once or twice at 6-7-d-long interval. The present innovation enables to improve metabolism, normalize the work of hormonal and nervous systems, normalize functions of uterine muscles at hypo- and atonias, at delayed afterbirth and restore affected ovarian functions.
EFFECT: higher efficiency of therapy.
FIELD: medicine, surgery.
SUBSTANCE: the present innovation deals with local treatment of erosive-ulcerous defects of skin and mucosa, inflammatory intestinal diseases and prolongly non healing wounds, among them. The method includes the use of diploid embryonic fibroblasts cultivated beyond the body, moreover, the fibroblasts should be pre-affected with dexametason at concentration of 10-4 M/l under culture conditions for 1 h followed by washing it from preparation and changing the medium. Then one should apply the developed supernatant in the form of local application onto affected area once daily. The method enables to decrease inflammatory manifestations in wounds and erosive-ulcerous defects of skin and mucosa, stimulates regenerative processes at minimal restrictions while applying the present innovation from the side of lesion section and decreases financial expenses.
EFFECT: higher efficiency of local treatment.
7 dwg, 2 ex, 6 tbl
FIELD: medicine, otorhinolaryngological surgery.
SUBSTANCE: one should apply thin layer of "Solcoseryl" gel onto osseous facial walls of frontal and maxillary sinuses at the border with trepanation opening after removing pathological content out of them and before applying a transplant out of flat bone of human fetal cranial arch that exceeds the diameter of trepanation opening by 3-4 mm. Then, one should additionally fix the transplant by affecting with distal edge part of a light guide of semi-conductor laser "ATKUS-15" with contact-type technique at output power of laser radiation being 8 W at constant mode. The method enables to increase fixation density of allobrefobone to osseous walls of sinus along its whole diameter.
EFFECT: higher efficiency of fixation.
FIELD: medicine, oncourology.
SUBSTANCE: the present innovation deals with treating locally spread tumor diseases of urinary bladder due to applying either chemo- and/or radiation therapy. Moreover, one should intravenously once inject by drops autologous mesenchymal stem cells (AMSC) at the quantity of 1 mln cells/kg patient's body weight. Moreover, in case of chemotherapy AMSC should be injected during the period before the 20-th d after the last injection of chemopreparation, in case of radiation therapy - 12-15 d against the day of irradiation. In case of chemoradiation therapy AMSC should be injected after chemotherapy before the course of radiation therapy. This method enables to carry out chemoradiation therapy in patients with severe accompanying diseases that prevent such a therapy, and prevent the development of general toxic complications of chemoradiation therapy and medicinal and radiation-caused cystitis.
EFFECT: higher efficiency of therapy.
3 ex, 2 tbl